128 related articles for article (PubMed ID: 38705320)
1. Co-assembly of cisplatin and dasatinib in hyaluronan nanogel to combat triple negative breast cancer with reduced side effects.
Liu R; Hou W; Li J; Gou X; Gao M; Wang H; Zhang Y; Deng H; Yang X; Zhang W
Int J Biol Macromol; 2024 Jun; 269(Pt 1):132074. PubMed ID: 38705320
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronan nanogel co-loaded with chloroquine to enhance intracellular cisplatin delivery through lysosomal permeabilization and lysophagy inhibition.
Gao M; Deng H; Zhang Y; Wang H; Liu R; Hou W; Zhang W
Carbohydr Polym; 2024 Jan; 323():121415. PubMed ID: 37940248
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.
Wei X; Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2013 Apr; 24(4):658-68. PubMed ID: 23547842
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
Xu Y; Liu D; Hu J; Ding P; Chen M
Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
8. Biomimetic "nano-spears" for CAFs-targeting: splintered three "shields" with enhanced cisplatin anti-TNBC efficiency.
Wu Y; Chen R; Ni S; Hu K
J Control Release; 2024 Jun; 370():556-569. PubMed ID: 38697316
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance.
Zhang Y; Zeng X; Wang H; Fan R; Hu Y; Hu X; Li J
Drug Deliv; 2021 Dec; 28(1):670-679. PubMed ID: 33792436
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
[TBL] [Abstract][Full Text] [Related]
11. pH-Responsive Fluorescence Enhanced Nanogel for Targeted Delivery of AUR and CDDP Against Breast Cancer.
Cao Z; Li W; Liu R; Li C; Song Y; Liu G; Chen Y; Lu C; Lu A; Liu Y
Int J Nanomedicine; 2020; 15():8369-8382. PubMed ID: 33149581
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan-fullerene/AIEgen nanogel as CD44-targeted delivery of tirapazamine for synergistic photodynamic-hypoxia activated therapy.
Hong X; Xu X; Liu Z; Liu S; Yu J; Wu M; Ma Y; Shuai Q
Nanotechnology; 2021 Aug; 32(46):. PubMed ID: 34325415
[TBL] [Abstract][Full Text] [Related]
14. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
15. Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: synthesis, pharmacokinetics, and tumor growth inhibition.
Wei X; Senanayake TH; Bohling A; Vinogradov SV
Mol Pharm; 2014 Sep; 11(9):3112-22. PubMed ID: 25072100
[TBL] [Abstract][Full Text] [Related]
16. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.
Agrawal S; Dwivedi M; Ahmad H; Chadchan SB; Arya A; Sikandar R; Kaushik S; Mitra K; Jha RK; Dwivedi AK
Nanomedicine; 2018 Feb; 14(2):327-337. PubMed ID: 29129754
[TBL] [Abstract][Full Text] [Related]
17. Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer.
Ding Y; Yang R; Yu W; Hu C; Zhang Z; Liu D; An Y; Wang X; He C; Liu P; Tang Q; Chen D
J Nanobiotechnology; 2021 May; 19(1):147. PubMed ID: 34011362
[TBL] [Abstract][Full Text] [Related]
18. CD44 targeted redox-triggered self-assembly with magnetic enhanced EPR effects for effective amplification of gambogic acid to treat triple-negative breast cancer.
Sang M; Han L; Luo R; Qu W; Zheng F; Zhang K; Liu F; Xue J; Liu W; Feng F
Biomater Sci; 2019 Dec; 8(1):212-223. PubMed ID: 31674634
[TBL] [Abstract][Full Text] [Related]
19. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
20. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
